October 29, 2020 | Blog
2020 USA Election & Drug Pricing Outlook
An analysis of the key drug pricing proposals in the 2020 USA Election in terms of political focus, party priorities, implementation feasibility, and potential risk to biopharma.
Anna Du
Senior Analyst
Anna Du is a Senior Analyst at CBPartners.
Connect with Anna Du
Published Articles
September 7, 2020 | Research posters
ISPOR Asia-Pacific 2020: China’s 2019 NRDL Update – Implications on Global & Local Manufacturer Strategy
A research poster to evaluate 2019 NRDL negotiation outcomes as indicators of potential strategic approaches for multinational and domestic manufacturers to achieve NRDL listing.
April 29, 2020 | Blog
Clinical Trial Disruptions: Can Small-Cap Biopharma Companies Weather the Impact of COVID-19?
Cumulative costs from patient enrollment scenarios due to COVID-19 will likely generate a significant financial drain on biopharma R&D expenditures. CBPartners' blog post investigates this impact and explores mitigation strategies.